Jessica J Waninger
Overview
Explore the profile of Jessica J Waninger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
540
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Waninger J, Demirci F, Demirci H
Can J Ophthalmol
. 2024 Oct;
PMID: 39366666
Objective: Conjunctival melanoma (CJM) is a rare subtype of mucosal melanomas. Despite an increasing understanding of CJM genetics, predicting patient prognosis remains challenging. Here we sought to see if a...
2.
Waninger J, Ayres B, Jayasundera K, Demirci H
Retin Cases Brief Rep
. 2023 Oct;
19(1):74-76.
PMID: 37824762
Purpose: To describe a case of perfluoro-n-octane (PFO) retention, migration into the anterior chamber, and the subsequent formation of iris nodules after the repair of a giant retinal tear. Methods:...
3.
Waninger J, Ma V, Chopra Z, Pearson A, Green M
Cancer J
. 2023 Oct;
29(5):279-284.
PMID: 37796646
The liver is a common site of metastasis for many primary malignancies, but the quantitative impact on survival is unknown. We performed a systematic review and meta-analysis of 83 studies...
4.
Fan K, Waninger J, Yentz S, McLean S, Demirci H
Ophthalmic Plast Reconstr Surg
. 2023 May;
39(5):e152-e155.
PMID: 37207285
The development of immune checkpoint inhibitors (ICI) has transformed the treatment of advanced-stage cutaneous melanoma; however, most trials did not include patients with conjunctival melanoma. Herein the authors describe a...
5.
Waninger J, Demirci H, Ayres B
Ophthalmology
. 2023 Jan;
130(12):1343.
PMID: 36682977
No abstract available.
6.
Li G, Choi J, Kryczek I, Sun Y, Liao P, Li S, et al.
Cancer Cell
. 2023 Jan;
41(2):304-322.e7.
PMID: 36638784
Immune checkpoint blockade (ICB) can produce durable responses against cancer. We and others have found that a subset of patients experiences paradoxical rapid cancer progression during immunotherapy. It is poorly...
7.
Waninger J, Fecher L, Lao C, Yentz S, Green M, Demirci H
Cancers (Basel)
. 2022 Dec;
14(23).
PMID: 36497270
Background: There is no standardized treatment for metastatic uveal melanoma (MUM) but immune checkpoint inhibitors (ICI) are increasingly used. While ICI has transformed the survival of metastatic cutaneous melanoma, MUM...
8.
Siebenaler R, Chugh S, Waninger J, Dommeti V, Kenum C, Mody M, et al.
PNAS Nexus
. 2022 Aug;
1(3):pgac084.
PMID: 35923912
Activating mutations in RAS GTPases drive nearly 30% of all human cancers. Our prior work described an essential role for Argonaute 2 (AGO2), of the RNA-induced silencing complex, in mutant...
9.
Ma V, Chamila Perera A, Sun Y, Sitto M, Waninger J, Warrier G, et al.
Front Immunol
. 2022 Jul;
13:860421.
PMID: 35874737
Background: Standard combination ipilimumab/nivolumab (I/N) is given as 4 induction doses for advanced stage melanoma followed by nivolumab single-agent maintenance therapy. While many patients receive less than 4 doses due...
10.
Waninger J, Beyett T, Gadkari V, Siebenaler R, Kenum C, Shankar S, et al.
Biochem Biophys Rep
. 2022 Jan;
29:101191.
PMID: 34988297
Oncogenic mutations in KRAS result in a constitutively active, GTP-bound form that in turn activates many proliferative pathways. However, because of its compact and simple architecture, directly targeting KRAS with...